Helix Biopharm (HBP.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 07/31
| 07-2020 | 07-2019 | 07-2018 | 07-2017 | 07-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,235 | 206 | 366 | 897 | 3,654 |
| Receivables | 180 | 290 | 315 | 630 | 489 |
| Other current assets | 155 | 0 | 0 | 0 | 0 |
| TOTAL | $4,660 | $687 | $773 | $1,700 | $4,233 |
| Non-Current Assets | |||||
| PPE Net | 246 | 253 | 374 | 487 | 235 |
| TOTAL | $246 | $253 | $374 | $487 | $235 |
| Total Assets | $4,906 | $940 | $1,147 | $2,187 | $4,468 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 1,416 | 3,040 | 1,992 | 1,438 | 715 |
| Accrued Expenses | 301 | 1,057 | 644 | 722 | 589 |
| Other current liabilities | 49 | N/A | N/A | N/A | N/A |
| TOTAL | $1,925 | $4,221 | $2,674 | $2,204 | $1,304 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 0 | 124 | 38 | 44 | N/A |
| Other Non-Current Liabilities | -587 | 0 | 0 | 0 | 0 |
| TOTAL | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $1,925 | $4,221 | $2,674 | $2,204 | $1,304 |
| Shareholders' Equity | |||||
| Common Shares | 137,257 | 129,532 | 125,565 | 120,681 | 116,146 |
| Retained earnings | -180,516 | -171,531 | -164,005 | -155,380 | -145,321 |
| Other shareholders' equity | 20,113 | 15,403 | 14,045 | 11,814 | 10,549 |
| TOTAL | $2,394 | $-3,281 | $-1,527 | $-17 | $3,164 |
| Total Liabilities And Equity | $4,319 | $940 | $1,147 | $2,187 | $4,468 |